Sign in

    Tony Pollock

    Senior Equity Research Analyst at Aegis Capital

    Tony Pollock is a Senior Equity Research Analyst at Aegis Capital Corp, specializing in the healthcare and biotechnology sectors. He covers companies such as BioCryst Pharmaceuticals, Sorrento Therapeutics, and Fortress Biotech, and has been recognized on platforms like TipRanks for maintaining a success rate of approximately 60% and generating solid average returns for investors. Pollock began his equity research career in the early 2000s, previously holding analyst roles at Cantor Fitzgerald and Maxim Group before joining Aegis Capital in 2016. He holds FINRA Series 7, 63, 86, and 87 licenses and is noted for his depth of market knowledge and robust financial analysis credentials.

    Tony Pollock's questions to MANULIFE FINANCIAL (MFC) leadership

    Tony Pollock's questions to MANULIFE FINANCIAL (MFC) leadership • Q4 2014

    Question

    Tony Pollock from Aegis Capital asked for an update on the Wabush iron ore project, questioning its potential profitability at current low prices if MFC were to regain control, and inquired about the payment status from the current lessee, Cliffs.

    Answer

    President and CEO Gerardo Cortina acknowledged that current iron ore prices make profitability difficult but noted that lower shipping costs and a favorable Canadian dollar exchange rate are positive factors. He stated any decision to restart the mine would require studies confirming economic viability. CFO Sam Morrow confirmed that Cliffs was making its lease payments on a quarterly basis.

    Ask Fintool Equity Research AI